Norouzzadeh Mostafa, Hasan Rashedi Minoo, Shahinfar Hossein, Rahideh Seyedeh Tayebeh
Student Research Committee, Iran University of Medical Sciences, Tehran, Iran; Nutritional Sciences Research Center, Iran University of Medical Sciences, Tehran, Iran; Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.
Student Research Committee, Iran University of Medical Sciences, Tehran, Iran; Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.
Diabetes Metab Syndr. 2024 May;18(5):103026. doi: 10.1016/j.dsx.2024.103026. Epub 2024 May 8.
This study aimed to clarify the effectiveness of tart cherries on anthropometric, lipid, and glycemic indices. We also aimed to clarify the appropriate dosage for this effect and suggest directions for future studies.
PubMed, Scopus, and Web of Science were searched until May 2022. Twelve eligible trials were included. The pooled results were reported as weighted mean differences (WMD) and 95 % confidence intervals (CIs). The Cochrane risk of bias and GRADE tools were used to assess the risk of bias and certainty of the evidence, respectively.
Tart cherry generally showed no significant effects on cardiometabolic risk factors. But subgroup analysis revealed that tart cherry significantly lowered total cholesterol (WMD: -0.33 mmol/l; 95 % CI: -0.55, -0.10), triglyceride (WMD: -0.19 mmol/l; 95 % CI: -0.26, -0.12), and low-density lipoprotein cholesterol (WMD: -0.36 mmol/l; 95 % CI: -0.58, -0.14), in unhealthy populations. Additionally, subgroup analysis indicated that the favorable effects of tart cherry were more pronounced in a single dose, longer duration, elderly, and obese individuals. Dose-response analysis revealed that 20 ml concentrate has the greatest effect in reducing total cholesterol (WMD: -0.40 mmol/l; 95 % CI: -0.61, -0.19), triglyceride (WMD: -0.23 mmol/l; 95 % CI: -0.33, -0.13), and elevating high-density lipoprotein cholesterol (WMD: 0.20 mmol/l; 95 % CI: 0.17, 0.22).
Tart cherry supplementation did not have significant effects on anthropometric and glycemic indices, but can improve lipid profile, especially in a single dose, longer duration, and in elderly, obese, and unhealthy individuals.
本研究旨在阐明酸樱桃对人体测量指标、血脂和血糖指标的有效性。我们还旨在明确产生这种效果的合适剂量，并为未来研究提供方向。
检索了截至2022年5月的PubMed、Scopus和Web of Science数据库。纳入了12项符合条件的试验。汇总结果以加权平均差（WMD）和95%置信区间（CI）报告。分别使用Cochrane偏倚风险工具和GRADE工具评估偏倚风险和证据的确定性。
酸樱桃总体上对心血管代谢危险因素无显著影响。但亚组分析显示，在不健康人群中，酸樱桃能显著降低总胆固醇（WMD：-0.33 mmol/l；95%CI：-0.55，-0.10）、甘油三酯（WMD：-0.19 mmol/l；95%CI：-0.26，-0.12）和低密度脂蛋白胆固醇（WMD：-0.36 mmol/l；95%CI：-0.58，-0.14）。此外，亚组分析表明，酸樱桃的有益作用在单次给药、较长疗程、老年人和肥胖个体中更为明显。剂量反应分析显示，20毫升浓缩液在降低总胆固醇（WMD：-0.40 mmol/l；95%CI：-0.61，-0.19）、甘油三酯（WMD：-0.23 mmol/l；95%CI：-0.33，-0.13）以及升高高密度脂蛋白胆固醇（WMD：0.20 mmol/l；95%CI：0.17，0.22）方面效果最佳。
补充酸樱桃对人体测量指标和血糖指标无显著影响，但可改善血脂状况，尤其是在单次给药、较长疗程以及老年人、肥胖者和不健康个体中。
